THE TAPE
TARS · Biotechnology · $3.5B

Tarsus Pharmaceuticals, Inc. Common Stock

$78.68▼ −1.99%
Last close
Relative strength
70RS
of 99, against every stock▲ +12 on the month
Powering up
Developing
+2.0%
six months against Biotechnology
52-week range
−14.0%
from the high
$53.89$91.53
Setup
squeezeforming
+1.6%
against the pivot at $77.47
No report date on the calendar.
Growth REALProof PENDING
Quarter to Sep 30, revenue +64% on a year ago
11/16 O 81.35 H 81.35 L 77.39 Vol 875.0K
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS70
vs pivot+1.56%
Tightening0.85×
Dry-up1.19×
Up/down vol-0.12
From high14%
failed pokeforming5 of 9checks
Previous breakout stopped out ▼ −10.23% in Sep
Powering up
Support and resistance
Support below
$76.66
-2.6% · tested 3× · last 11 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 2.2 weeks and fell 16% from its ceiling at its deepest. The pivot is $77.47, and the stock closed 1.6% above that pivot. Its relative strength rating is 70.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+12.3%
Three months against its industry
+18.1%
Six months against its industry
+2.0%

Read against an equal-weighted index of Biotechnology, which is +22.6% against the S&P 500 over six months Partly aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 7.5% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$682.2M
+63.9% year on year
Operating margin
-102.0%
Net margin
-102.9%
Free cash flow
$32.4M
0.9% of market cap
Price to sales
5.06×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 3
Key takeaway
Real growth, but execution and cash generation are not yet proven.
Revenue
$194.6M
+11.9% QoQ · +63.9% YoY
Gross margin
—
Net income
−$668.3M
Loss
Free cash flow
−$7.2M
Burning · 19q runway

What the numbers say

  • Good: Revenue +63.9% year over year, +11.9% on the quarter
  • Weak: Net loss $668M, wider than $19M last quarter
  • Weak: Burning cash: operating cash flow -$6M, free cash flow -$7M, worse than $57M last quarter · 19 quarters of cash at this burn
  • Weak: Growth externally funded: capex $1M against operating cash flow -$6M; share count +9.0% in a year
  • Good: Net cash $64M · cash $137M
Revenue by quarter
Free cash flow
Net income
shares +9.0% in a year · net cash $63.6M

What is not obvious

  • Weak: Stock compensation $27M added back against negative operating cash flow
  • Weak: Interest $2M a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: REAL · Economic proof: PENDING
Key question: Can the growth turn into durable profit and cash after its costs and financing?
The next test is operating profit: net loss $668M, wider than $19M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-05
below 20d & 50d on 2.8x volume at 69.07
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
Unusual volumeTape · 2026-11-05
3.1 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Reported resultsFiling · 2026-11-04
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
GappedTape · 2026-10-24
-5.4%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Earnings date movedEvent · 2026-10-21
2026-11-02 -> 2026-11-10
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
Red flag in a filingFiling · 2026-10-14
going concern
No measurable effect: stocks behave like random ones over the next three sessions (1,160 cases over 54 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
19
$7,510,413 total

Sold: LINK WILLIAM J PHD, Azamian Bobak R., Lin Elizabeth Yeu, Neervannan Seshadri, Farrow Jeffrey S, Goodrich Katherine.

Not counted above: 10 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-09-15 PYOTT DAVID E I · Directoroption exercise201
2026-09-15 YARNO WENDY L · Directoroption exercise302
2026-09-15 LINK WILLIAM J PHD · Directoroption exercise201
2026-09-15 LINK WILLIAM J PHD · Directorsell11,675$914,503
2026-09-15 LINK WILLIAM J PHD · Directorsell759$59,961
2026-09-15 LINK WILLIAM J PHD · Directorsell66$5,281
2026-09-04 Azamian Bobak R. · President/CEO and Board Chair, Directorsell7,100$640,917
2026-09-04 Azamian Bobak R. · President/CEO and Board Chair, Directorsell2,900$264,683

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$77.47
Wrong below$64.37
Measured target · a squeeze has no height to projectnone
Leaning · and strengtheningup
Length2.2 weeks

Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.

What lines up

5 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy1
Buy9
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
10w · 29%

The most recent of 3 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Tarsus Pharmaceuticals, Inc. Common Stock (TARS) — The Tape